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A n g i o t e n s i n - c o n v e r t i n g  e n z y m e  ( A C E )  i s  a  p e p t i ­
d a s e  r e s p o n s i b l e  f o r  t h e  c l e a v a g e  o f  a n g i o t e n s i n  I  
a n d  s e v e r a l  o t h e r  p e p t i d e s .  H e r e ,  g e n e  t a r g e t i n g  
w a s  u s e d  t o  s w i t c h  c o n t r o l  o f  t h e  A C E  l o c u s  f r o m  
t h e  e n d o g e n o u s  p r o m o t e r  t o  t h e  m a c r o p h a g e - s p e -  
c l f i c  c-fms p r o m o t e r .  C h a l l e n g e  o f  t h e s e  m i c e ,  
c a l l e d  A C E  1 0 / 1 0 ,  w i t h  t h e  a g g r e s s i v e  m o u s e  m e l a ­
n o m a  c e l l  l i n e  B l 6  s h o w e d  t h a t  t h e y  a r e  r e m a r k a b l y  
r e s i s t a n t  t o  t u m o r  g r o w t h .  T u m o r  r e s i s t a n c e  w a s  
s e e n  a f t e r  c h a l l e n g e  w i t h  d i f f e r e n t  m e l a n o m a  c e l l  
l i n e s  a n d  i n  m i c e  w i t h  d i f f e r e n t  g e n e t i c  b a c k ­
g r o u n d s .  H i s t o l o g i c a l  s t u d y  o f  t h e  t u m o r s  t h a t  d i d  
g r o w  i n  A C E  1 0 / 1 0  m i c e  s h o w e d  a n  e n h a n c e d  i n ­
f l a m m a t o r y  r e s p o n s e .  A C E  1 0 / 1 0  m i c e  h a d  i n ­
c r e a s e d  n u m b e r s  o f  t u m o r  e p i t o p e - s p e c i f i c  C D 8 +  T  
c e l l s  a f t e r  c h a l l e n g e  w i t h  m e l a n o m a  o r  l y m p h o m a .  
A C E  1 0 / 1 0  m a c r o p h a g e s  s h o w e d  i n c r e a s e d  p r o d u c ­
t i o n  o f  i n t e r l e u k i n - 1 2  a n d  n i t r i c  o x i d e  b u t  r e d u c e d  
i n t e r l e u k i n - 1 0 .  E n g r a f t m e n t  o f  w i l d - t y p e  m i c e  w i t h  
A C E  1 0 / 1 0  b o n e  m a r r o w  t r a n s f e r r e d  B l 6  t u m o r  r e ­
s i s t a n c e .  I n j e c t i o n  o f  B l 6  t u m o r s  w i t h  A C E  1 0 / 1 0  
m a c r o p h a g e s  a l s o  r e d u c e d  t u m o r  g r o w t h .  A C E  
1 0 / 1 0  m i c e  m a y  d e f i n e  a  n e w  m e a n s  o f  e n h a n c i n g  
t h e  i m m u n e  r e s p o n s e ,  w h i c h  m a y  b e  p o t e n t i a l l y  
u s e f u l  i n  s e v e r a l  h u m a n  c l i n i c a l  s i t u a t i o n s .  (A m  J  
Palhol 2007, 170:2122-21.i t; DOT: 10.2353/ajpalh.2007.061205)
The renin-angiotensin system (RAS) is an enzymatic cas­
cade producing the active octapeptide angiotensin II 
from angiotensinogen.1 This occurs in two consecutive 
steps catalyzed by renin and angiotensin-converting en­
zyme (ACE). Whereas renin is very precise in its sub­
strate specificity, ACE is more promiscuous. Angiotensin
I and bradykinin are well-known physiological substrates, 
but ACE also cleaves substance P, AcSDKP, /3-endor­
phins, and several other peptides. Perhaps because of 
this variety of substrates, ACE affects many physiological 
processes including blood pressure, hematopoiesis, and 
fertility.2 Indeed, ACE may occasionally play an immuno­
logical role as indicated by Nakagawa et al3 and Ko- 
slowski et al,4 who showed that ACE is important in the 
production of the immunodominant epitope of the human 
immunodeficiency virus 1 protein gp160. Finally, ACE 
has been implicated in several pathological processes, 
such as atherosclerosis and diabetic nephropathy.5 6
ACE is a zinc-dependent carboxypeptidase. Several 
different tissues express ACE, but it is the expression of 
large amounts of ACE by vascular endothelium that is 
responsible for the bulk conversion of angiotensin I to 
angiotensin II. All somatic tissues that express ACE make 
a protein containing two independent catalytic domains.7 
This is distinct from the ACE isozyme made by develop­
ing male germ cells, which is called testis ACE. Testis 
ACE is catalytic, but this protein is smaller than the so­
matic enzyme. Somatic ACE and testis ACE arise be­
cause the ACE gene has two distinct promoter regions.2 8
Previously, the physiology of ACE was investigated 
using genetically modified mice lacking all ACE.9-10 Such 
ACE-null mice have a complicated phenotype character­
ized by low blood pressure, the inability to concentrate 
urine, structural renal defects, anemia, and reduced male 
fertility. In an attempt to reduce this complexity, our group 
used gene targeting to make genetic mouse models in 
which ACE expression was limited to a small group of 
tissues. Specifically, gene targeting in mouse embryonic 
stem cells was used to transfer the expression of somatic 
ACE from the endogenous somatic ACE promoter to 
other promoter regions.11
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Here, we describe a mouse model called ACE 10/10, 
in which gene targeting was used to substitute ACE 
expression from the endogenous promoter to the c-fms 
promoter. These mice express high ACE levels in mac­
rophages and macrophage-like cells but lack ACE in 
such traditional locations as blood vessels and kidney. 
ACE 10/10 mice were originally conceived as a model to 
study the relationship between enhanced macrophage 
ACE expression and atherosclerosis. However, while we 
were characterizing these animals, we realized that ACE 
10/10 mice have a very unexpected phenotype: a 
marked resistance to the growth of an aggressive and 
commonly used tumor model, B16 melanoma. ACE 10/10 
mice respond to melanoma challenge with an enhanced 
inflammatory response, including increased tumor-spe­
cific CD8+ T cells; macrophages from these mice re­
spond to stimuli with an enhanced “MT activation profile 
characterized by increased interleukin (IL)-12 and nitric 
oxide but decreased 11-10. Direct transfer of macro­
phages or engraftment of wild-type mice with ACE 10/10 
bone marrow transferred B16 tumor resistance. If ACE 
10/10 mice define a general yet simple means of enhanc­
ing immunity, this may be useful to human tumor therapy 
as well as in other clinical settings.
Materials and Methods
Materials
Lipopolysaccharide (IPS) (Escherichia coli 055:B5) was 
from Sigma-Aldrich (St. Louis, MO). Murine 11-10 and 
IL-12/p40 enzyme-linked immunosorbent assay kits were 
purchased from eBioscience (San Diego, CA). Griess 
reagents were from Promega (Madison, Wl), and the 
Griess assay was performed according to the manufac­
turer's instructions. ACE activity was measured using the 
ACE-REA kit from American Laboratory Products Com­
pany, Ltd. (ALPCO, Windham, NH) as previously de­
scribed.11 ACE activity was defined as that inhibited by 
captopril.
Creation o f ACE. 10 Homozygous Mutant Mice
A neomycin cassette (called KT3NP4) was inserted into a 
unique BssHII restriction site located within the 5' un­
translated region of somatic ACE.11 A 7.2-kb fragment of 
DNA encoding the mouse c-fms promoter, the first and 
second c-fms exons, and the first and second introns 
were positioned immediately 3' to the neomycin cassette 
within the targeting vector. The c-fms promoter had pre­
viously been modified so that the translation start site, 
normally present in exon II, was no longer functional.1213 
The promoter was obtained from David Hume (University 
of Queensland, Queensland, QLD, Australia). Targeted 
homologous recombination was performed as previously 
described.11 Age-matched littermate controls were used 
in all studies. Animal procedures were approved by the 
Institutional Animal Care and Use Committee and were 
supervised by the Emory Division of Animal Research.
Antibodies and Tetramer
Immunohistochemistry of paraffin-embedded tissue was 
performed with polyclonal rabbit anti-mouse ACE,8 rat 
anti-mouse F4/80 (Serotec, Oxford, UK), and rat anti­
human CD3 (Serotec). The antibodies were developed 
using biotinylated goat secondary antibodies (Vector 
Laboratories, Burlingame, CA), the VECTASTAIN 
ABC-AP (alkaline phosphatase) kit (Vector Laboratories), 
and Vector Red substrate. Other antibodies used for 
immunofluorescent microscopy or fluorescence-acti­
vated cell sorting (FACS) analysis were from BD Bio­
sciences, Serotec, or eBioscience. Phycoerythrin-conju- 
gated SVYDFFVWL tetramer was synthesized by the 
National Institutes of Health Tetramer Core Facility. Allo- 
phycocyanine-conjugated SIINFEKL tetramer was a gift 
from Dr. John D. Altman (Emory University).
Cells and Tumor Model
The B16-F10 melanoma cell line was obtained from the 
American Type Culture Collection (Manassas, VA). The 
B16-LS9 melanoma cell line was obtained from Hans E. 
Grossniklaus (Emory University). The B16/OVA mela­
noma cell line was obtained from Edith M. Lord (Univer­
sity of Rochester). The E.G7-OVA cell line was obtained 
from Kyle McKenna (Emory University). Before use, the 
melanoma cell monolayer was detached with phosphate- 
buffered saline containing 0.25% trypsin and 0.03% eth- 
ylenediamine tetraacetic acid, washed, and counted. The 
cell concentration was adjusted to 1 x 107 cells/ml, and 
100 /nl of the suspension was injected intradermally into 
the dorsal skin using a 26-gauge needle under anesthe­
sia. The size of the tumor was measured using a caliper. 
The tumor volume was calculated according to the for­
mula (V = [L x W 2} x 0.52), where V is volume, L is 
length, and W  is width (length is greater than width).14
Inhibitors
ALZET osmotic minipumps (Cupertino, CA) were placed 
subcutaneously. Captopril was dosed at 6 mg/kg per 
day, whereas losartan was given at 30 mg/kg per day for
2 weeks. Blood pressure measurements by tail cuff ver­
ified the effectiveness of the drugs in reducing blood 
pressure.
Bone Marrow Transplantation
ACE 10 mice were back-crossed to C56BL/6 mice for a 
total of 7 generations. These mice expressed the CD45.2 
allele. Bone marrow was obtained from 8-week-old ACE 
10/10 and littermate ACE wild-type donor mice by flush­
ing femurs and tibiae with RPMI 1640 medium. Nucleated 
cells were counted, and the bone marrow was resus­
pended at a concentration of 2 x 107/ml. Recipient mice 
were 8-week-old C57BL/6, 10 of whom expressed the 
CD45.1 allele, whereas five expressed CD45.2. Recipi­
ents were irradiated with 1100 rads and then were imme­
diately reconstituted with either 2 x 106 ACE 10/10 or
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wild-type bone marrow cells via retroorbital injection. Af­
ter 8 weeks, the recipient mice were analyzed by FACS 
for blood leukocyte expression of CD45 alleles, ACE, and 
markers of myeloid and T cells.
T Cell Depletion
On days -2 , -1 , 1, and 7, F2 ACE 10/10 mice were 
injected intraperitoneally with 250 /xg of monoclonal an­
tibodies YTS 169.4.2.1 (anti-mouse CD8; Emory Vaccine 
Center) or GK1.5 (anti-mouse CD4; Emory Vaccine Cen­
ter). A second group of control ACE 10/10 mice was 
injected with class-matched rat IgG.
Macrophage Expansion
For later experiments, bone marrow was obtained from 6- 
to 8-week-old donor mice. This was cultured for 7 days in 
media containing 15% L929 cell-conditioned media as 
previously described.15 The conditioned media provide 
macrophage-colony-stimulating factor and results in a 
pure population of macrophages.
Results
Targeted homologous recombination in mouse embry­
onic stem cells was used to modify the ACE gene and 
substitute control of ACE expression to a c-fms promoter 
cassette (Figure 1A). This cassette, containing both the 
first and second introns of the c-fms gene, was previously
ng gene expression to 
neage cells.1213 Proper 
ed, and chimeric mice
shown to be selective in targetii 
macrophages and macrophage I 
homologous targeting was veriffc 
were bred to produce agouti F1 and then F2 mice. Ho­
mozygous mutant mice are termed ACE 10/10, since this 
was the 10th ACE line made in our laboratory. Of 441 F2 
mice genotyped, 26% were wild type, 49% were het­
erozygous, and 26% were ACE 10/10. ACE 10/10 mice 
appeared grossly normal, with normal organ weight/body 
weight ratios.
To study the tissue distribution of ACE, organ extracts 
from wild-type, heterozygous, and ACE 10/10 mice were 
tested for ACE activity (Figure 1B). Whereas a wild-type 
mouse has abundant lung and renal ACE activity, ACE 
10/10 mice had a reduction of approximately 98% in 
pulmonary ACE and no detectable renal ACE. In contrast, 
ACE 10/10 mice had a 20-fold increase of ACE activity in 
spleen compared with wild type. As for plasma ACE, 
there were no significant differences between wild-type, 
heterozygous, or ACE 10/10 mice.
Western blot analysis of tissue extracts confirmed the 
marked reduction of lung ACE and the lack of renal ACE 
in ACE 10/10 mice (Figure 1C). It also verified that these 
mice have much more splenic ACE protein than wild-type 
animals. We also performed ACE activity assays and 
Western blot analysis of macrophages collected after 
peritoneal thioglycollate injection. Both assays showed 
little ACE activity in cells derived from wild-type mice but
abundant ACE in cells from ACE 10/10 mice (Western 
blot shown in Figure 1C, bottom).
Standard blood analyses of ACE 10/10 mice were not 
significantly different from wild-type mice. These animals 
have normal quantities of red and white blood cells. 
Histological study of peripheral blood smears also 
showed no significant differences. FACS analysis of bone 
marrow and spleen showed normal quantities of T, B, and 
myeloid cells (data not shown).
To investigate the expression of ACE by hematopoietic 
tissues, FACS analysis was performed on white blood 
cells collected from the blood, spleen, bone marrow, and 
peritoneal washes (Figure 1D). Individual cell populations 
were stained with an anti-ACE antibody and antibodies to 
either CD3 (T cells), B220 (B cells), CD11b (monocytes 
and macrophages), F4/80 (macrophages), or Gr-1 (neu­
trophils and other myeloid cells). Controls included iden­
tically prepared cells from wild-type mice and a previ­
ously reported line of mice called ACE 4/4 that is null for 
ACE expression, except for male germ cells.16 Because 
the two control populations gave identical results, we only 
show data from wild-type mice. When cells were gated 
and compared for the level of ACE expression, no ACE 
expression was detected in the T or B cells of either ACE 
10/10 or control mice. A high level of ACE expression, 
however, was detected on the monocytes/macrophages 
from ACE 10/10 mice; mean channel fluorescence was 
about 16-fold higher than that of monocytes/macro­
phages from wild-type or ACE 4/4 mice. Neutrophils are 
cells of myeloid origin, and these cells from ACE 10/10 
mice showed a fourfold increase of ACE fluorescence 
compared with controls. Splenic CD11c+ cells from ACE 
10/10 mice also mildly overexpressed ACE. Thus, FACS 
confirms our hypothesis that ACE 10/10 mice have ACE 
expression targeted to macrophages and macrophage 
lineage cells. Indeed, monocytes and macrophages 
markedly overexpress ACE.
Analysis of blood pressure by tail cuff showed that 
ACE 10/10 mice have systolic blood pressures equivalent 
to wild-type and heterozygous mice (ACE 10/10, 100 ± 1 
mm Hg; wild type, 99 ± 1 mm Hg; heterozygous, 94 ± 1 
mm Hg, n >20/group). In addition, renal concentrating 
function was similar in ACE 10/10 and wild-type mice.
To investigate inflammation and tumor growth, we in­
jected 1 x 106 B16-F10 melanoma cells intradermally 
into F2 wild-type, heterozygous, and ACE 10/10 mice. 
B16-F10 melanoma is an aggressive cell line that will give 
rise to a tumor nodule in most mouse lines.17 At days 11 
and 14 after injection, tumor size was measured and total 
tumor volume calculated. These experiments uncovered 
a profound and consistent difference between wild-type 
and ACE 10/10 mice (Figure 2, A and B). At 14 days, 
wild-type mice averaged tumors of 540 ± 83 mm3; ACE 
10/10 and heterozygous mice averaged tumors of 90 ± 
18 and 252 ± 43 mm3, respectively (P <  0.001 com­
pared with wild type).
To see whether tumor resistance was unique to the 
B16-F10 cell line, we performed an identical experiment 
using a different strain of mouse melanoma cells called 
B16-LS9 (Figure 2C). These cells also produced much 
larger tumors in wild-type mice than in ACE 10/10. To this
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Figure 1. ACE expression, in. ACE 10/10 m ice. A: T h e  to p  o f  th e  figure sh o w s th e  w ild -tvpe  o rgan iza tion  o f  th e  ACE locus. Both th e  somatic: ACE p ro m o ter an d  
th e  testis ACE p ro m o te r a re  in d ica ted  w ith  arrows. In. th e  ACE 10/10 g en e  (b o tto m ), h o m o lo g o u s  reco m b in a tio n  w as used, to  position, a neo m y cin  resistance  
cassette  (N eo K)  a n d  a 7 .2-kb c-fm s  p ro m o ter casse tte  su ch  th a t th e  structu ral p o rtio n  o f  th e  ACE g e n e  is n o w  u n d e r  th e  con tro l o f  th e  c -fm s  p rom o ter. B: ACE 
activity w as m e asu red  in. organ, h o m o g e n a te s  o f  w ild -tvpe (w /w ) , he te ro zy g o u s (w t/1 0 ), a n d  ACE 10/10 m ice. ACE activity is ex p re ssed  as  un its  p e r  m illigram  
to ta l so lub ilized  pro te in . T h e  data  a re  th e  g ro u p  m e an s  ±  SEM o f  6 to  10 ind iv idual m ice. C: T h e  to p  p an e l sh o w s tissue  h o m o g e n a te s  from  w ild -type  (W T), 
h e terozygous (H Z ), a n d  ACE 10/1010 m ice  th a t w e re  stu d ied  b y  W este rn  b lo t analysis u s ing  a rabb it anti-ACE an tibody . Somatic: ACE (sACE) is a b a n d  o f  ab o u t 
170 k d , w h e reas  testis  ACE (tACE) is a b o u t 100 kd . T h e  b o tto m  p an e l sh o w s ACE W estern  b lo t analysis o f  perito n ea l m a c ro p h ag es  co llec ted  after th ioglycollate 
injection. In. c on tras t to  w ild  type , ACE 10/10 m a c ro p h ag es  ex p ress  a b u n d a n t ACE. D : FACS w as p e rfo rm ed  on. w h ite  cells from  th e  b lo o d  a n d  perito n ea l lavage 
o f  w ild -type a n d  ACE 10/10 m ice. Cells w e re  s ta ined  w ith  a po lyc lonal rabb it anti-ACE an tib o d y  a n d  costa in ed  w ith  an tib o d y  aga in st CD3, B220, G r-1, o r  F4/80. 
T h e  u p p e r  portion, o f  th e  figure sh o w s th a t m a c ro p h ag es  (F 4 /80  b righ t ce lls) a n d  neu tro p h ils  (G r-1 b righ t ce lls) from  ACE 10/10 m ice  ex p ress  app rox im ate ly  16- 
a n d  fourfo ld  m o re  ACE (as  estim ated  b y  m e a n  fluo rescen t activity) than, th e se  cells from  w ild -tvpe  m ice. T h e  lo w er portion, o f  th e  figure sh o w s a h istogram  o f  
th e  ACE sta in ing  for B cells (B220 b righ t), T  cells (CD 3 b righ t), m acro p h ag es , a n d  neu troph ils . T h e  so lid  line sh o w s ce lls from  ACE 10/10, w h e reas  th e  d o tted  
line sh o w s equ iv a len t da ta  from  w ild -tvpe  m ice. Similar da ta  w e re  fo u n d  in. ce lls from  sp lee n  a n d  b o n e  m arrow .
point, all experiments were performed in F2 generation 
mice, which are a genetic mix of 129 and C57BL/6 back­
grounds. To understand further the ACE 10/10 pheno­
type, mice were bred with outbred CD-1 (Swiss) mice 
and then challenged with intradermal injection of B16- 
F10 melanoma cells (Figure 2D). Again, ACE 10/10 mice 
showed much smaller tumors than those observed in 
wild-type mice (ACE 10/10, 104 ± 33 mm3; wild type, 
552 ± 134 mm3; P < 0.01). Thus, in different genetic 
backgrounds and challenged with different melanoma 
cell lines, ACE 10/10 mice showed a profound resistance 
to the growth of tumors. ACE 10/10 mice inbred to 
C57BL/6 are discussed below.
Insight into the mechanism operating in the ACE 10/10 
mice was obtained by histologically examining tumors 
present in wild-type and ACE 10/10 animals (Figure 3). A
major difference was in the quantity of inflammatory cells 
observed within the blood vessels of the tumors. Al­
though tumors present in wild-type mice contain very few 
intravascular white blood cells (Figure 3A), these cells 
were abundant in ACE 10/10 tumor blood vessels (Figure 
3B). At times, vessels were almost engorged by the white 
cell response (Figure 3C). Immunohistochemical analysis 
of tumors from ACE 10/10 mice showed that the vast 
majority of intravascular cells were strikingly positive for 
ACE expression (Figure 3D). Histologically, these cells 
resembled monocytes, and immunofluorescence 
showed that most of these cells stained for CD11b (Fig­
ure 3E). In addition, within the tumor were phagocytic 
cells that also stained intensely for ACE (Figure 3F). 
These cells histologically resembled macrophages, con­
tained phagocytized melanin, and immunostained for
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A ACE 10 mice -- B16-F10 melanoma
Figure 2. In crea sed  resistance  to  m elanom a in 
ACE 10/10 m ice. A: M ice s h o w n  in. p ane ls  a, fo, 
d, an d  e are  th re e  pairs o f  litte rm ate m ice 14 
days  after in jection  o f  B16-F10 m elanom a cells. 
ACE 10/10 m ice (10 /1 0 ) consisten tly  have d ra ­
m atically  sm aller tu m o rs  than, w ild -type  (W T) 
m ice, c: Skin, flaps a n d  su b cu ta n eo u s  m ela­
nom a (arrow) from  th e  m ice pictured, in. a and  
fo. B: ACE 10/10 (10 /10 ), h e terozygous (H Z), 
a n d  W T m ice w e re  injected, in traderm ally  with. 
B16-F10 m elanom a cells ( n  — 11, 10, an d  10). 
A t 11 a n d  14 days  after injection, tu m o r v o lum e 
w as  m easu red . M ean  values  ±  SEM are  s h o w n  
to  th e  righ t o f  th e  ind iv idual data  po in ts. T h e  P  
v a lues  at 14 d ays w ere : W T versus  10/10, P  <  
0.0005; W T versus  HZ, P  -  0.001; an d  H Z 
versus  10/10, P  -  0.039. C: F2 W T a n d  ACE 
10/10 (10 /1 0 ) m ice w ere  in jected  with. B16-LS9 
m elanom a cells. T u m o r size w as  m easured, as 
desc rib ed  abo v e  (  n  — 5, P  <  0.02 at day  14). D : 
ACE 10/10 m ice w ere  mated, with. C D -I m ice, 
a n d  heterozygous o ffspring  w e re  th e n  bred, to  
p ro d u ce  W T an d  ACE 10/10 m ice. M ice w ere  
in traderm ally  in jected  with. B16-F10 m elanom a 
cells a n d  ana lyzed  as  desc rib ed  abo v e  ( n  — 10, 
P  <  0.01 at day  14).
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F4/80 (Figure 3G). Finally, we identified some T cells 
(CD3-positive cells) within the 10/10 tumors (Figure 3H). 
Thus, histological analysis indicates a greater inflamma­
tory response within the small tumors of ACE 10/10 mice.
If an enhanced immune response is responsible for the 
increased tumor resistance of ACE 10/10 mice, then the 
transfer of bone marrow might endow a wild-type mouse 
with increased resistance to melanoma. This was tested 
by first back-breeding the ACE 10/10 mice to C57BL/6 
mice for 7 generations. On average, such mice (termed
F7) have genomes greater than 99% identical to 
C57BL/6. Bone marrow was harvested from littermate F7 
wild type and F7 ACE 10/10 mice and engrafted into 
lethally irradiated C57BL/6 mice. After allowing for re­
population of the marrow, engraftment was checked by 
FACS analysis of blood leukocytes for CD11b and ACE 
expression. In addition, some recipient mice were a con- 
genic strain of C57BL/6 having the CD45.1 allele, 
whereas all donor marrow was from mice with the CD45.2 
allele. After engraftment, the recipient animals were
Increased Macrophage ACE and Melanoma 2127
AJPJune 2007, Vol. 170, No. 6
checked by FACS for leukocyte CD45.1 and CD45.2 
expression. Such analyses showed that by 8 weeks, vir­
tually all myeloid cells and nearly all T cells were of donor 
origin. The engrafted C57BL/6 mice were then chal­
lenged by intradermal injection of B16-F10 cells, and at 2 
weeks, tumor size was evaluated (Figure 4). These data 
showed a highly significant difference in tumor size be­
tween C57BL/6 mice receiving ACE 10/10 bone marrow 
versus wild-type bone marrow (ACE 10/10, 168 ± 22 
mm3; wild type, 330 ± 29 mm3; P < 0.0005). Thus, 
transfer of ACE 10/10 bone marrow to wild-type recipi­
ents transferred significant resistance to melanoma 
growth.
ACE 10/10 mice have several differences from wild- 
type mice. Although the most obvious is increased ACE 
expression by macrophages and macrophage-like cells, 
ACE 10/10 mice also lack ACE expression by tissues 
such as endothelium. Such was not the case when all 
recipient mice were wild-type C57BL/6 with normal en­
dothelial ACE expression (Figure 4). To address further 
the question of endothelial ACE, we implanted B16-F10 
tumor into the skin of a different line of mice, termed ACE 
3/3, which express ACE in the liver but completely lack 
endothelial ACE.11 Unlike ACE 10/10, these mice showed 
no difference from wild type in tumor growth (data not 
shown). Thus, the lack of endothelial ACE does not ex­
plain the resistance of ACE 10/10 mice to melanoma.
Angiotensin II is the most important product of ACE in 
a wild-type mouse, and most of the effects of angiotensin
II are mediated by the AT1 receptor. To investigate the 
role of angiotensin II in the ACE 10/10 model, we studied 
six groups of mice implanted with B16-F10 melanoma: 
ACE 10/10, wild type, both ACE 10/10 and wild type 
treated with the ACE inhibitor captopril, and both ACE 
10/10 and wild type treated with the AT1 receptor blocker 
losartan (Figure 5A). Both captopril (by blocking ACE) 
and losartan (by blocking the angiotensin II receptor) 
reduced systolic blood pressure from approximately 105 
mm Hg to below 80 mm Hg. Wild-type mice treated with 
either captopril or losartan showed a slower growth of the 
tumor compared with untreated wild-type mice. Perhaps 
this was because of the effects of the acute and substan­
tial blood pressure reduction during the 2-week assay. 
However, quite different results were seen with ACE 
10/10 mice. Whereas these two drugs reduced the sys­
tolic blood pressure to an equivalent degree as seen in 
wild-type mice, the ACE 10/10 mice treated with captopril 
showed a more rapid growth of the melanoma as com­
pared with untreated ACE 10/10 mice. In fact, there was 
no statistical difference in tumor growth between wild- 
type and ACE 10/10 mice when both groups were treated 
with captopril. In contrast, blocking the AT1 receptor of 
ACE 10/10 mice with losartan had no significant effect on 
B16-F10 tumor growth. Further, we have examined six 
mice that are angiotensinogen (agt)-knockout-ACE 10/
10. Genetically eliminating agt makes it impossible to 
produce angiotensin II (and other angiotensin peptides). 
If angiotensin II was critical for the ACE 10/10 phenotype, 
then agt-ACE 10/10 mice should be equivalent to agt- 
ACE wild-type mice. However, as seen in Figure 5B, the 
agt-ACE 10/10 double knockout mice resisted B16-F10
tumors much more effectively than agt-ACE wild-type 
mice (P < 0.0005). Thus, the captopril experiments 
strongly suggest that it is the presence of ACE, and not its 
absence, that is important in the resistance of ACE 10/10 
mice to melanoma growth. However, both pharmacolog­
ical and genetic approaches suggest that angiotensin II 
is not the critical element in understanding the ACE 10/10 
mice. As discussed below, we believe that resistance to 
melanoma in ACE 10/10 mice is mediated by immuno­
logical mechanisms and not by aberrant angiotensin II 
production.
To understand the immune response in ACE 10/10 
mice, we infused these mice with monoclonal antibodies 
directed at either CD4+ or CD8+ T cells. This manipula­
tion eliminated greater than 90% of the appropriate T 
cells while not greatly affecting the CD11b+ cells. ACE 
10/10 mice lacking CD8+ T cells are highly susceptible to 
B16-F10 tumor growth (Figure 6A). Indeed, at 14 days, 
tumors in ACE 10/10 mice lacking CD8+ T cells averaged 
nine times greater than tumors in control ACE 10/10 mice 
(ACE 10/10 depleted of CD8+ T cells, 1026 ± 140 mm3; 
ACE 10/10 treated with control antisera, 114 ± 20 mm3). 
In contrast, when ACE 10/10 mice were depleted of only 
CD4+ T cells, there was no effect on tumor growth.
CD8+ T cells become activated when their T cell re­
ceptors recognize peptides presented within major 
histocompatibility complex class I proteins. To measure 
tumor-reactive T cells, both ACE 10/10 and littermate 
wild-type mice were intradermally injected with B16/OVA 
cells, which is a B16 melanoma line (B16-F1) stably al­
tered to produce ovalbumin.18 Tumor size was measured 
on day 14 and again showed enhanced tumor resistance 
in ACE 10/10 mice as compared with wild type (Figure 
6B, left panel). We also measured the number of blood 
CD8+ T cells recognizing known immunodominant 
epitopes by using tetramer reagents and FACS analy­
sis.19 One such epitope reported for the B16 melanoma 
is the tyrosinase-related protein 2 (TRP-2) peptide SVY- 
DFFVWL (TRP-2180_188).20 In addition, we measured the 
frequency of CD8+ T cells recognizing the ovalbumin 
epitope SIINFEKL (0VA257_264). For both epitopes, there 
was a highly significant increase in the frequency of 
CD8+ tetramer+ T cells in ACE 10/10 mice (Figure 6B, 
center and right panels, P < 0.01 for both TRP-21ao_1aa 
and 0VA257_264). The data in Figure 6 strongly suggest 
that ACE 10/10 mice have an enhanced immune re­
sponse to B16 melanoma due, at least in part, to in­
creased expansion of tumor epitope-specific T cells.
ACE 10/10 mice also show a different phenotype of 
effector molecule and cytokine production compared 
with wild-type mice. To examine this, we first developed a 
straightforward way to obtain relatively pure “tumor-in­
duced macrophages.'’ The protocol was to inject F7 mice 
intradermally with 3 x 10s B16 melanoma cells. Eight 
days later, 5 x 10s melanoma cells were injected into the 
peritoneum. Four days later (day 12), the mice were 
sacrificed, and collected peritoneal cells were adhered to 
plastic to isolate macrophages. These cells were washed 
and then cultured for 24 hours without any additional 
stimulation. At that point, we measured the nitrite levels (a 
stable end product of nitric oxide) in the culture medium
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Figure 4. ACE 10/10  b o n e  m arro w  transplantation , con fers  tu m o r im m unity. 
C57BL/6 m ice w ere  le thally  irrad iated  a n d  th e n  im m ediately  tran sp lan ted  
with, b o n e  m arrow  from  e ith e r ACE 10/10  o r  litte rm ate w ild -type (W T ) m ice 
( n  — 12 p e r  g ro u p ). A fter engraftm ent, th e  m ice w ere  ch a llen g ed  b y  intra- 
derm al in jection  o f  B16-F10 m elanom a cells. T u m o r v o lum e w as m easured, at
11 a n d  14 days after injection. M ean  values  ±  SEM are  s h o w n  to  th e  right o f  
th e  ind iv idual da ta  poin ts. O n  day  14, th e  P  v a lue  w as P  <  0.0005.
(Figure 7A).21 This showed that ACE 10/10 macrophages 
increased the levels of nitrite produced by wild-type cells 
by greater than 10-fold (ACE 10/10, 5.22 ± 1.4 /urmol/L; 
wild type, 0.42 ± 0.1 /urmol/L; P < 0.01).
One may argue that the above experiment reflects 
enhanced in vivo immune activation due to several pos­
sible mechanisms. So to study a simpler system, macro­
phages from F7 wild-type and ACE 10/10 mice (without 
any exposure to tumor) were collected 4 days after peri­
toneal instillation of thioglycollate. The cells were then 
cultured without additional stimulation for 16 hours. Fi­
nally, either interferon (IFN)-y or IPS was added for 24 
hours, and nitrite levels were measured (Figure 7A, cen­
ter and right). In the absence of stimulation, no nitrites 
were detected. However, in response to either IFN-y or 
IPS, ACE 10/10 macrophages produced significantly 
more nitrites than cells from wild-type mice. For example, 
in response to IFN-y, ACE 10/10 cells averaged 3.6 ± 0.5 
/nmol/L, whereas wild-type cells averaged 1.2 ± 0.4 
/nmol/L (P < 0.005).
We also measured 11-12 production. For this, tumor- 
induced macrophages were prepared as described 
above. On day 12 of the protocol, the peritoneal macro­
phages were adhered to plastic and treated for 24 hours 
with IPS, IFN-y, or the combination LPS/IFN-y. An en­
zyme-linked immunosorbent assay was then used to 
measure IL-12p40 levels in the culture media. Without 
stimulation, or with the addition of just IFN-y, no IL-12p40
was found (Figure 7B). With either IPS alone or IPS and 
IFN-y, ACE 10/10 macrophages produced substantially 
more cytokine than control macrophages. For example, 
LPS/INF-y induced 11,939 ± 1054 pg/ml IL-12p40 from 
ACE 10/10 macrophages but only 6389 ± 1289 pg/ml 
from control macrophages (P < 0.005).
The above experiments showed that ACE 10/10 mac­
rophages respond to a variety of stimuli with enhanced 
11-12 production. This question was also evaluated in 
ACE 10/10 and wild-type mice by measuring plasma 
levels of IL-12p40 (Figure 7C). Without tumors, there was 
no difference in plasma levels of this protein (ACE 10/10, 
661 ± 11 pg/ml; wild type, 659 ± 80 mg/ml, n = 4 for 
each group). However, 14 days after the intradermal 
implantation of B16 melanoma, ACE 10/10 mice aver­
aged 2346 ± 123 pg/ml plasma IL-12p40 compared with 
1704 ± 146 pg/ml plasma IL-12p40 for wild-type mice 
(n = 10 for each group, P < 0.005).
In studying nitrites and IL-12, we focused on molecules 
associated with immune activation. In contrast, IL-10 is 
associated with immune suppression.22 To examine this 
in the ACE 10/10 system, we prepared tumor-induced 
macrophages, as previously described, in F7 mice bear­
ing B16 melanoma. We also prepared macrophages from 
mice without tumor by collecting peritoneal macrophages 
in response to thioglycollate. The tumor-induced macro­
phages were cultured without further stimulation, 
whereas the thioglycollate-induced cells were stimulated 
with 1000 ng/ml LPS. After 6 hours, the culture superna- 
tants were collected and IL-10 levels determined by en­
zyme-linked immunosorbent assay. As shown in Figure 
7D, ACE 10/10 macrophages produced less IL-10 than 
wild-type cells, either in response to tumor or after LPS 
challenge. For example, tumor-induced macrophages 
from ACE 10/10 mice averaged 148 ± 30 pg/ml IL-10; 
equivalently prepared cells from wild-type mice aver­
aged 366 ± 67 pg/ml (n = 7, P < 0.02). Thus, macro­
phages from ACE 10/10 mice respond to stimuli with 
increased numbers of tumor-specific T cells, and a dif­
ferent phenotype of cytokines and effector molecules 
compared with macrophages from wild-type mice.
If ACE 10/10 macrophages demonstrate enhanced im­
mune activation, then the transfer of such cells should 
confer a clinical advantage. As previously discussed in 
Figure 4, bone marrow transplantation with ACE 10/10 
bone marrow did just this. In addition, we tried a simpler 
protocol where wild-type C57BL/6 mice were implanted 
intradermally with B16-F10 melanoma. After 7 days, all 
animals had a small skin tumor. Each animal then re­
ceived a single intratumor injection of 2 x 106 macro­
phages from either ACE 10/10 or littermate wild-type
Figure 3. E nh an ced  inflam m atory  resp o n se  to  m elanom a in. ACE 10 /10  m ice. B16-F10 m elanom as from  a w ild -type (A) an d  ACE 10 /10  m ice (B-H) w ere  ex am in ed  
m icroscopically . T h e  m ost im pressive d iffe rence w as in. th e  quan tity  o f  inflam m atory  cells o b served  w ith in  th e  b lo o d  vessels  o f  th e  tum or. A lthough, tum ors  from  
w ild -type m ice co n ta in  very  few  in travascu lar w h ite  b lo o d  cells (A, arrow), th e se  ce lls w e re  a b u n d a n t in. ACE 10/10  tu m o r b lo o d  vessels  (B, arrow). At tim es, 
vessels  w e re  a lm ost e n g o rg ed  b y  a w h ite  ce ll resp o n se  (C, arrow). Im m unochem ical analysis o f  tum ors  with. an. anti-ACE an tibody  (D) show ed, th a t th e  g rea t 
m ajority o f  in travascu lar cells w e re  strong ly  positive fo r ACE ( th e  red. p ig m en t indicated, by  th e  arrow). Further, th e se  cells s ta in ed  with. an ti-C D llb , a 
m o n o c y te /m acro p h a g e  m arker (E, a n t i-C D llb  is g reen , w h ereas  anti-CD31, an. endo th e lia l m arker, is co lo red  b lue). Inflam m atory  cells w e re  a lso  fo u n d  ou ts ide  
o f  blood, vessels  w ith in  th e  tum ors  o f  ACE 10 /10  mice. T h ese  cells histologically  resem b led  m acrophages  a n d  c o n ta in ed  p h agocy tized  m elanin . T hey  sta in ed  
in tensely  fo r  ACE (F, g ro u p  o f  p ink  ce lls in d ica ted  by  th e  arrow). T hey  a lso  im m unosta ined  fo r th e  m acro p h ag e  m a rk er F4/80  (G, red. ce ll ind ica ted  by  arrow). 
As ex p e c ted , m onocy tes  w ith in  b lo o d  vessels  (G, asterisk) d id  n o t stain, fo r  F4/80. Finally, som e C D 3+ T  cells w e re  fo u n d  w ith in  th e  10/10  tum ors  (H, red. ce ll 
indicated, b y  arrow). H ow ever, m ost cells w ith in  b lo o d  v esse ls  w e re  n o t lym phocy tes b u t w e re  m onocy tic  (H, asterisk).
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Figure 5. ACE is critical fo r tu m o r resistance. A: ACE 10/10 a n d  w ild -tvpe (W T) m ice w e re  co m p ared  with, m ice receiv ing  e ith e r 2 w eek s  o f  captopril. o r  2 w eek s  
o f  lo sa rtan  by  m in ipum p. O n e  d ay  after p u m p  p lacem en t, m ice w e re  injected, with. B16-F10 m elanom a cells in. a location  rem oved, from  th e  m in ipum ps. T um or 
size w as m easured. 2 w eek s  after m elanom a im plantation . M ean  values ±  SEM are  s h o w n  to  th e  right o f  th e  ind iv idual data poin ts. As d e te rm in ed  u sing  analysis 
o f  variance  w ith T u k e v ’s honestly  significantly  different, th e re  is a significant d iffe rence betw een. ACE 10/10 ( n  = 1 2 )  a n d  ACE 10/10 captopril. ( n  — 6, P  <  0 .01). 
In. con trast, th e re  is n o  significant d iffe rence betw een. ACE 10/10  an d  ACE 10/10 losartan. ( n  — 8, P  <  0 .99). Further, th e re  is n o  significant d ifference betw een. 
ACE 10/10 captopril. a n d  e ith e r w ild  type , w ild -tvpe cap topril, o r  w ild -tvpe  losartan. ( n  — 11, 6, 8; P  <  0.39 o r  grea ter). B: All m ice in. th is  figure lack 
ang io ten sin o g en  exp ress ion . T h e  ACE g en o ty p e  is e ith e r ACE 10/10  ( n  — 6)  o r  w ild  ty p e  (W T, n  — 7). All m ice w ere  cha llenged  b y  in traderm al in jection  o f  
B16-F10 m elanom a cells. T u m o r v o lum e w as m easured, a t 11 a n d  14 days after injection. M ean  values  ±  SEM are s h o w n  to  th e  right o f  th e  ind iv idual data  points. 
O n  d av  14, th e  P  v a lue  w as P  <  0.0005.
mice. These macrophages were derived from bone mar­
row and harvested from donor mice without any exposure 
to tumor. The marrow was induced to expand and differ­
entiate into a pure population of macrophages by culture 
with conditioned media.15 Seven days after macrophage 
injection (day 14 of the experiment), tumor size was mea­
sured (Figure 8A). Mice receiving intratumor injections of 
ACE 10/10 macrophages had significantly smaller tumors 
than animals receiving an equivalent injection of wild- 
type macrophages (ACE 10/10, 435 ± 86 mm3 versus 
control, 816 ± 104 mm3; P < 0.01). Although results 
varied among individual animals, the transfer of ACE
10/10 macrophages sometimes produced very dramatic 
involution of tumors, as seen in Figure 8B.
Finally, we studied the immune response of F7 ACE 
10/10 mice to one other tumor besides melanoma. This 
was E.G7-OVA, an ovalbumin-expressing derivative of 
the mouse lymphoma line EL4 23 The protocol was to 
inject 3 x 105 tumor cells subcutaneously and then mea­
sure both tumor nodule size and blood CD8+ tetramer+ 
cells for SIINFEKL. Similar to what was noted with mela­
noma, ACE 10/10 mice had slower growth of the E.67- 
OVA tumor and a higher frequency of CD8+ tetramer+ 
cells than littermate wild-type mice (Figure 9). These data
o
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Figure 6. T  cells in. ACE 10/10 m ice. A: ACE 10/10 m ice w ere  d e p le te d  o f  CD4 o r  CDS T  cells b y  in traperitoneal in jections o f  rat m o noc lona l an tibody  as ind icated  
in. th e  figure. C ontro l m ice received, equ iv a len t in jections o f  c lass-m atched  rat IgG. FACS analysis sh o w e d  tha t th e  m o noc lona l an tibod ies d e p le te d  m o re  th a n  90% 
o f  th e  targeted. T  cells. T h e  m ice w ere  ch a llen g ed  b y  in traderm al in jection  o f  B16-F10 m elanom a cells, a n d  tu m o r size w as m easu red  on. d ay  14. M ean  values ±  
SEM are  sh o w n  to  th e  right o f  th e  ind iv idual data  po in ts  ( n  — a t leas t 8 fo r each, g ro u p ). B: ACE 10/10  o r  con tro l m ice w ere  in traderm ally  in jec ted  with. B 16/OVA 
a n d  tu m o r size  w as m easu red  on. d ay  14 (left p ane l). P eriphera l b lo o d  w as a lso  ana lyzed  b y  FACS u s in g  anti-CD8 an tib o d y  a n d  te tram ers con ta in in g  th e  p ep tid e  
e p ito p e s  0'VA.257_264 (m idd le  p an e l)  an d  TRP-2180_188 (righ t p an e l) . D ata a re  reported, as th e  pe rcen tage  o f  CD8+ cells tha t a lso  sta in ed  fo r th e  ind iv idual te tram ers 
( n — 7 fo r each, g roup ).
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Figure 7. Nitrite an d  cy tok ine  re sp o n se  o f  ACE 10/10 m ice. A: T um o r-in d u ced  m a c ro p h ag es  (TIM ) w e re  o b ta in ed  from  ACE 10/10 o r  w ild -type  CWT) m ice  as 
desc rib ed  in. Results. T h e se  w e re  cultured, fo r 24 hou rs , a n d  n itrite  levels w e re  m easured, in. th e  cu ltu re  m ed ia  u sing  th e  G riess reagen t. M acrophages from  ACE 
10/10  a n d  w ild -type  m ice  w e re  also  obtained, after th iog lyco llate  injection, in to  th e  p e ritoneum . A fter cu ltu re  overn igh t, th e  ce lls w e re  treated, with, e ith e r IFN-7 
(100 U /m l) o r  LPS (1  /xg/m l) fo r 24 hou rs , a n d  n itrite  levels w e re  m easured, in. th e  cu ltu re  m ed ia . Mean, va lues ±  SEM a re  show n, to  th e  right o f  th e  indiv idual 
data p o in ts  ( n  — a t leas t 7 fo r each, g ro u p , P  <  0.01 fo r each, o f  th e  th re e  pan e ls). B : TIM w e re  obtained, from  ACE 10/10 o r  W T m ice  as  desc rib ed  in. Results. T h ese  
w e re  a d h e re d  to  p lastic  a n d  rested, fo r 16 hou rs. T hey  w e re  then, cultured, fo r an. add itiona l 24 ho u rs  in. th e  p re se n c e  o f  e ith e r IFN-7 o r  LPS as ind icated . Finally, 
IL-12 levels w e re  m easured, in. th e  cu ltu re  m ed ia  ( n  — 10, P  <  0.005 fo r LPS and. I.PS/IFN-7). C : IL-12 levels in. p lasm a w e re  m easured, in. m ice  w ith o u t tum ors 
(Control.) o r  14 days  after skin, im plantation, o f  B l6 m e lanom a (T u m o r) ( n  — 4 fo r each. C ontro l g roup ; n  — 10 fo r each. T u m o r g ro u p ). Although. ACE 10/10 an d  
w ild -type  m ice  free o f  tu m o rs  h av e  n o  a p p a re n t d iffe rence in. p lasm a IL-12 levels, m ice  with, tum ors  d o  sh o w  a d ifference, with, h ig h e r p lasm a levels p re sen t in. 
ACE 10/10  m ice . D : TIM w e re  o b ta in ed  from  ACE 10/10 o r  W T m ice. T h e se  w e re  a d h e re d  to  p lastic  a n d  cultured, fo r 6 hou rs, an d  IL-10 levels in. th e  supem.atan.ts 
w e re  then, m easured, by  enzym e-linked  im m u n o so rb en t assay. L ow er IL-10 w as p re sen t in. su p em a tan ts  from  ACE 10/10 m acro p h ag es  co m p ared  with, su p em a tan ts  
from  w ild -type  m acro p h ag es . T h iog lyco llate-induced  m a c ro p h ag es  w e re  also  co llec ted  from  m ice  w ith o u t tum ors. T h e se  w e re  cu ltu red  fo r 6 ho u rs  with. 1000 
n g /m l LPS. A gain, th e  su p em a tan ts  from  ACE 10/10 m acro p h ag es  co n ta in ed  significantly  less IL-10 (ACE 10/10, 133 ±  13 p g /m l; w ild  type , 242 ±  30 p g /m l, n  —
8, P  <  0 .01).
suggest that the enhanced immune response of ACE 
10/10 mice is not limited to only B16 melanoma.
Discussion
The study of tumor growth in ACE 10/10 mice was stim­
ulated by articles suggesting that blockade of ACE or the 
AT, receptor may reduce tumor growth, perhaps through 
effects on tumor angiogenesis.24~26 To our surprise, the 
ACE 10/10 mice did not show accelerated tumor growth 
but a consistent and marked resistance to tumor prolifer­
ation. We believe that the antitumor effect observed in
ACE 10/10 mice is due to ACE overexpression by mac­
rophages and macrophage-lineage cells: only these cells 
express ACE in ACE 10/10 mice, ACE inhibition elimi­
nates the effect, and the effect is transferable into wild- 
type mice through bone marrow transplantation.
ACE 10/10 mice markedly overexpress ACE in macro­
phages and macrophage-like cells. This is true because 
these cells make substantial ACE, but it is also true 
because macrophages from wild-type mice typically 
make little ACE (see Figure 1C). The marked overexpres­
sion of ACE in ACE 10/10 mice is almost pharmacologi­
cal, and the behavior of this model has little bearing on
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Figure 8. Intra tu m o r injection, o f  m acro p h ag es . A: C57BL/6 m ice  w ere  im p lan ted  with, tum or. O n  day  7, th e  tum ors  w e re  in jec ted  with, e ith e r 2 X 106 m acro p h ag es  
from  ACE 10/10  o r  litterm ate w ild -type (W T) m ice. T u m o r size  w as m e asu red  on. day  14. M ean, va lues  ±  SEM are  show n, to  th e  righ t o f  th e  ind iv idual data po in ts  
( n  — a t least 15 fo r each, g ro u p , P  <  0 .01). B: A  p ic tu re  o f  tw o  m ice  treated, as  desc rib ed  in. A. T he m o u se  on. th e  left w as in jec ted  with, w ild -type m acrophages , 
w h e reas  th e  anim al on. th e  righ t w as  in jec ted  with. ACE 10/10 m acrophages .
the immunological resistance of humans treated with 
ACE inhibitors. To our knowledge, no one has found that 
patients treated with ACE inhibitors were immunocom­
promised by the therapy.
In this article, we demonstrate that ACE 10/10 mice re­
spond to B16 challenge with an enhanced immune re­
sponse. There is an increased frequency of tumor-specific 
CD8+ lymphocytes and evidence of increased cytokines 
such as 11-12 and effector molecules such as nitric oxide. 
The result is much slower growth of the tumors. In recent 















F ig u r e  9* Increased  resistance  to  E.G7-OVA in. ACE 10/10 m ice. E.G7-OVA, 
an. ovalbum in -exp ress ing  derivative o f  th e  m o u se  lym phom a line EL4, w as 
in jected  in to  th e  su b cu ta n eo u s  tissue o f  e ith e r ACE 10/10 o r  w ild -type m ice. 
At day  16, th e  size o f  th e  tu m o r no d u le  w as m e asu red  (left p an e l) . P eripheral 
blood, w as  also  ana lyzed  by  FACS u sing  an.ti-CD8 an tibody  and. te tram ers 
con ta in ing  th e  p ep tid e  e p ito p es  OVA.257_264 (righ t pane l). D ata a re  reported, 
as th e  p erce n tag e  o f  C D 8+ tetram er'*' cells. Mean, va lues  ±  SEM are  show n, to  
th e  righ t o f  th e  ind iv idual data po in ts  ( n  — a t least 9 m ice  for each, g roup , P —
0.01 fo r th e  left p an e l an d  P  <  0 .02 for th e  righ t pane l).
of macrophages to tumor challenge can be broadly classi­
fied along two major pathways.27-28 One pathway produces 
what is referred to as “classical" macrophage activation. 
Such macrophages are characterized by a high capacity to 
present antigen, high 11-12 production, and high production 
of nitric oxide and other reactive intermediates. Macro­
phages with this phenotype, often referred to as M1, are the 
cells that are thought to participate in eliminating microor­
ganisms and in killing tumor cells.
It has also been recognized that in an inflammatory re­
sponse, there is often a resolution phase in which macro­
phages have a different set of developmental characteris­
tics.29 These “alternatively activated" or M2 macrophages 
are described as hyporesponsive to proinflammatory stimuli 
and often show enhanced IL-10 production. Such cells 
participate in debris salvaging and wound healing. It is also 
thought that some tumor-associated macrophages resem­
ble M2 macrophages in their behavior and that these mac­
rophages may promote tumor growth.30 Thus, a simplistic 
but perhaps useful way of looking at the role of macro­
phages in tumor immunity is as a balance between M1 
macrophages that destroy tumors and M2 tumor-associ­
ated macrophages that tend to promote tumor growth.
The concept of M1 and M2 macrophages is relevant to 
the ACE 10/10 model. These mice respond to melanoma 
with increased numbers of tumor-specific CD8+ cells, 
increased macrophage IL-12, increased nitric oxide, and 
decreased IL-10, all characteristics indicating a tilt to­
ward a classically activated (M1) phenotype. The exag­
gerated propensity to express the phenotypic markers of 
the M1 developmental pathway provide a partial expla­
nation for the enhanced tumor resistance of ACE 10/10 
mice.
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Of course, a major question is how the overexpression 
of the peptidase ACE leads to a phenotypic change in 
macrophages. We examined whether the ACE 10/10 
phenotype was due to angiotensin II, the classical end 
product of ACE. Although an ACE inhibitor reversed the 
ACE 10/10 phenotype, inhibition of the major angiotensin
II receptor, the AT, receptor, had no such effect. In 
addition, we created ACE 10/10 mice that also geneti­
cally lacked the ability to produce angiotensinogen. 
Here, the control mice were wild type for ACE expression 
but also lacked angiotensinogen. If angiotensin II was a 
critical player in the ACE 10/10 phenotype, we would 
expect that the loss of angiotensinogen would have ren­
dered these mice susceptible to B16 tumor growth. In 
fact, ACE 10/10 mice lacking angiotensinogen were sub­
stantially more resistant to tumor growth than the control 
mice. Thus, two separate approaches suggest that the 
underlying behavior of ACE 10/10 mice is not critically 
dependent on angiotensin II.
Certainly, one of the major functional roles of macro­
phages is the presentation of peptides. Can ACE, a 
rather nonspecific peptidase, play a role in this process? 
Our group has no direct evidence for or against this 
hypothesis. However, Eisenlohr et al31 overexpressed 
ACE in fibroblasts and then used vaccinia viral infection 
as a method to transfect these cells with DNA encoding 
influenza peptides or pro-peptide precursors. Peptide 
trimming and major histocompatibility complex class I 
presentation to influenza-sensitive CD8+ CTL was mea­
sured by a chromium release/cell killing assay. Specifi­
cally, this study asked if the overexpression of ACE could 
convert pro-peptides, including a 12-amino acid nucleo- 
protein peptide not recognized by CTL, into nine- or 
10-amino acid peptides detected by the CTL T-cell re­
ceptor. The answer was yes, and in establishing this, 
Eisenlohr et al31 provided evidence that ACE, acting 
internally at the endoplasmic reticulum, could trim pre­
cursor peptides into a size optimal for loading, presenta­
tion, and CTL recognition. In the future, our group hopes 
to study whether such a mechanism can enhance anti­
gen presentation in ACE 10/10 macrophages, perhaps 
providing a partial explanation for the ACE 10/10 
phenotype.
However, it is likely that the effects of ACE overexpres­
sion may be due to more than one mechanism. This is 
suggested by experiments in Figure 7A, which examined 
nitrite expression of cultured ACE 10/10 macrophages 
exposed to LPS. These experiments found clear differ­
ences in the expression of nitrites between cells from 
ACE 10/10 mice and control animals. What makes this in 
vitro experiment notable is that it was performed in cells 
from animals lacking any exposure to tumor. The lack of 
tumor antigens suggests intrinsic differences in the be­
havior of ACE 10/10 macrophages in response to LPS, an 
agent that acts through well described cell surface re­
ceptors.32 Thus, the overexpression of ACE may change 
the fundamental phenotype of how ACE 10/10 macro­
phages respond to a stimulus such as LPS.
In summary, ACE 10/10 mice exhibit enhanced resis­
tance to melanoma (B16-F10, B16-LS9, and B16-F1) and 
lymphoma (EL4). Macrophages from these mice respond
to stimuli with an enhanced classically activated (M1) 
phenotype, including increased numbers of specific 
CD8+ cells, increased IL-12, and decreased IL-10. If the 
study of ACE 10/10 mice leads to a means of enhancing 
immunity, this may be useful in a variety of human clinical 
situations.
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